Cardiac Biomarker Interpretation in Canine and Feline Practice

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-11

Key Takeaways

• Cardiac troponin I (cTnI) indicates myocardial injury, while N-terminal pro-B-type natriuretic peptide (NT-proBNP) reflects myocardial wall stretch and hemodynamic stress; select assays based on the specific clinical question.
• NT-proBNP elevations are common in dyspneic patients and have a high negative predictive value for congestive heart failure (CHF) in dogs, aiding differentiation from respiratory causes.
• Both cTnI and NT-proBNP are cleared renally, necessitating cautious interpretation of elevated values in azotemic patients due to impaired clearance, particularly for NT-proBNP.
• Biomarker results are most valuable when interpreted within the context of pretest probability, and a single borderline value rarely establishes a diagnosis, often requiring repeat testing and integration with imaging.
• Systemic inflammatory conditions, sepsis, and trauma can elevate cardiac biomarkers through multifactorial pathways, indicating myocardial injury but not necessarily primary cardiac disease.
• Species-specific interpretation is crucial: NT-proBNP is more useful for staging myxomatous mitral valve disease in dogs, while in cats, it aids in supporting a cardiomyopathy diagnosis when echocardiography is unavailable.

Cardiac biomarker testing has become a routine component of the diagnostic evaluation for dogs and cats with suspected heart disease. This article provides a structured framework for interpreting cardiac troponin I (cTnI) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) in clinical practice, with emphasis on diagnostic reasoning, test selection, and result interpretation across common clinical scenarios. The content is directed at practicing veterinarians who already understand basic cardiovascular pathophysiology and seek a practical reference for integrating biomarker data into their diagnostic workflow.

The central questions addressed are straightforward but consequential. When does a biomarker result change management? How should borderline values be handled? What conditions confound interpretation? The answers depend on understanding the biology of biomarker release and clearance, the analytical characteriztics of available assays, and the pretest probability of cardiac disease in the patient being evaluated. Biomarker testing supports, but does not replace, careful physical examination, thoracic auscultation, and imaging when available Oyama, using cardiac biomarkers in veterinary practice.

This reference is organized into four parts. Part 1 establishes the physiologic basis of biomarker release and clearance, defines the assays available to the practitioner, and outlines the interpretive principles that govern all subsequent clinical applications. Later parts address specific diagnostic scenarios, prognostic applications, and monitoring strategies.

At a Glance

Physiologic Basis of Biomarker Release

Natriuretic Peptides

B-type natriuretic peptide (BNP) is synthesized by ventricular myocardium in response to increased wall stress. The prohormone proBNP is cleaved into the biologically active BNP and the inactive N-terminal fragment, NT-proBNP. The N-terminal fragment has a longer half-life than the active hormone, making it more stable and easier to measure in clinical samples. Secretion increases when ventricular filling pressures rise, whether from volume overload, pressure overload, or myocardial failure. The magnitude of elevation reflects the degree of hemodynamic stress instead of the specific underlying disease Oyama, using cardiac biomarkers in veterinary practice.

Interpretation requires awareness of noncardiac influences. Renal dysfunction reduces clearance of NT-proBNP, producing elevations that do not necessarily indicate cardiac disease. Age and body condition score also influence circulating concentrations in dogs. The biomarker therefore functions as an indicator of myocardial stretch, and the clinician must integrate the result with the complete clinical picture.

Cardiac Troponin

Cardiac troponin I is a regulatory protein unique to myocardium. It exists in a structurally bound pool within the sarcomere and a smaller cytosolic pool. Myocardial injury releases troponin into the circulation, and the magnitude of release correlates with the extent of membrane disruption. Unlike NT-proBNP, troponin elevation indicates cellular injury instead of functional stress. Causes include ischemic injury, inflammatory myocarditis, trauma, toxins, and chronic myocardial remodeling.

Troponin I is highly specific for myocardial tissue, but it is not specific for any particular cardiac disease. A dog with a splenic mass and an elevated cTnI may have myocardial injury from hypovolemic shock, a cardiac metastasis, or an unrelated primary cardiomyopathy. The test answers one question: has myocardial injury occurred? Determining why that injury occurred requires additional investigation.

Assay Considerations

Available Formats

Veterinary practitioners can choose between point-of-care analyzers and laboratory-based immunoassays. The two formats are not interchangeable. Point-of-care devices offer rapid turnaround, which is valuable in emergency settings, but they generally have different analytical performance characteriztics than laboratory assays. Reference intervals established for one platform do not transfer to another. Clinicians should use the reference interval supplied by the laboratory or manufacturer for the specific assay in use.

Sample Handling

NT-proBNP is relatively stable in whole blood and serum, but samples should be processed promptly to avoid degradation. Hemolysis interferes with immunoassay performance and should be avoided. Troponin is more stable than NT-proBNP, but the same principles of prompt processing apply. When serial monitoring is planned, use the same assay platform throughout to minimize analytical variation.

Interpretive Framework

Pretest Probability

Biomarker results are most useful when interpreted in the context of pretest probability. A middle-aged Cavalier King Charles Spaniel with a murmur and cough has a high pretest probability of myxomatous mitral valve disease. An elevated NT-proBNP in that patient confirms hemodynamic significance but adds little diagnostic information. The same biomarker result in a young cat with tachypnea and no murmur carries far greater diagnostic weight. Biomarker testing should be deployed when the result will change the diagnostic plan, not as a routine screening tool in every patient with a murmur Oyama, using cardiac biomarkers in veterinary practice.

The Two-Question Rule

Every biomarker result should be interpreted by asking two questions. First, does the result support or refute the working diagnosis? Second, does the result change management? If the answer to the second question is no, the test may not have been indicated. This framework prevents reflexive testing and focuses interpretation on clinical action.

Borderline Values

Biomarker concentrations near the upper reference limit present the greatest interpretive challenge. A single borderline value rarely establishes a diagnosis. Repeat testing after a short interval, integration with physical examination findings, and additional diagnostic testing such as thoracic radiography or echocardiography are appropriate next steps. The biomarker result is one data point in a multidimensional diagnostic picture.

Biomarker Biology in Systemic Disease

Renal Function

Both NT-proBNP and cTnI are affected by renal function, although through different mechanisms. NT-proBNP clearance is directly impaired by reduced glomerular filtration, producing elevated concentrations in azotemic patients without primary cardiac disease. Troponin elevations in renal disease may reflect true myocardial injury from uremic cardiomyopathy, volume overload, or concurrent hypertension. In either case, renal dysfunction complicates interpretation and requires a cautious approach to diagnosis Girombelli et al., acute cardio-renal and reno-cardiac syndromes in critical care.

Noncardiac Critical Illness

Systemic inflammatory conditions, sepsis, and trauma can elevate cardiac biomarkers through multiple pathways. Hypotension reduces myocardial perfusion, inflammatory cytokines directly injure cardiomyocytes, and neurohormonal activation increases wall stress. An elevated troponin in a septic patient therefore does not prove primary cardiac disease. It does identify a patient with myocardial injury who may benefit from closer hemodynamic monitoring.

Limitations and Failure Modes

The most common interpretive error is overinterpretation of a single elevated value. Biomarkers are sensitive indicators of myocardial stress or injury but lack etiologic specificity. A second common error is using biomarkers to rule out cardiac disease when clinical suspicion is high. A normal NT-proBNP does not exclude structural heart disease, particularly in early or mild cases. The third failure mode is assay mismatch, where results from different platforms are compared as though they were equivalent.

Biomarker testing in veterinary medicine continues to evolve, and the evidence base for specific clinical applications is stronger in some areas than others. The clinician should apply these tests with an understanding of their strengths and limitations, using them to support clinical judgment instead of replace it.

Clinical Application: The Dyspneic Patient

The most common indication for cardiac biomarker measurement in small animal practice is the differentiation of cardiac from respiratory causes of dyspnea. This distinction is clinically urgent because the initial treatments diverge sharply. Furosemide given to a patient with pneumonia or bronchial disease can precipitate hypovolemia and renal injury. Bronchodilators and corticosteroids given to a patient with congestive heart failure (CHF) may worsen tachycardia and anxiety without addressing pulmonary edema.

The diagnostic sequence begins before blood is drawn. Signalment, physical examination, thoracic auscultation, and point-of-care ultrasound, where available, should be integrated with biomarker results. A middle-aged to older small-breed dog with a left apical systolic murmur, sinus rhythm, and pulmonary crackles has a high pretest probability of CHF. A young cat with a gallop rhythm and tachypnea but no murmur presents a more ambiguous picture. Biomarker testing adds the most value in the intermediate-probability patient, not in the patient where the diagnosis is already clear.

The Two-Question Rule Applied

For any dyspneic patient, the clinician asks two questions. First, is the respiratory sign cardiac or noncardiac in origin? Second, if cardiac, is the disease severe enough to require acute intervention?

For the first question, NT-proBNP is the preferred assay. In dogs, a negative NT-proBNP result, below the reference interval, makes CHF an unlikely cause of respiratory distress. In cats, the same logic applies, but the clinician must account for the wider biologic variability and the overlap between asymptomatic hypertrophic cardiomyopathy and mild respiratory disease. A single markedly elevated NT-proBNP concentration, for example greater than three times the upper reference limit, supports a cardiac cause of dyspnea in both species. Borderline elevations, within 20 percent of the upper limit, do not discriminate reliably and should be interpreted in light of imaging findings.

For the second question, cardiac troponin I provides complementary information. Troponin elevation indicates myocardial injury but does not distinguish acute from chronic injury. A normal troponin concentration does not exclude CHF, because myocardial injury is not a prerequisite for pulmonary edema. Conversely, a markedly elevated troponin in a dyspneic patient with known cardiac disease suggests an acute ischemic or inflammatory component that may warrant additional monitoring.

Decision Flowchart for Dyspneic Patients

The flowchart assumes that assay-specific reference intervals are applied. A result reported as "normal" or "elevated" by the laboratory must be interpreted against the published validation data for that assay and species. Assay performance varies between point-of-care and laboratory-based platforms, and the clinician should know which platform generated the result.

Monitoring Chronic Heart Failure

Serial biomarker measurement has a defined role in monitoring treated heart failure, but the role is narrower than once hoped. The resting respiratory rate, measured at home by the owner, remains the most sensitive and specific indicator of impending CHF decompensation. Biomarkers supplement, not replace, this measurement.

In dogs with myxomatous mitral valve disease, a rising NT-proBNP concentration over serial measurements may precede the onset of CHF by weeks to months. The clinical utility of this lead time depends on whether earlier intervention changes outcome. Current evidence does not support initiating pimobendan or diuretics based on biomarker trend alone in asymptomatic dogs. The decision to start therapy should rest on clinical signs, radiographic evidence of cardiomegaly or pulmonary edema, and echocardiographic staging.

In cats with hypertrophic cardiomyopathy, serial NT-proBNP measurement is less useful. The biologic variability of the assay in cats is substantial, and a single elevated value does not predict progression to CHF in an individual patient. Troponin measurement in cats is most useful as a prognostic indicator. Cats with persistently elevated troponin concentrations have a higher risk of adverse events, including CHF and arterial thromboembolism. A normal troponin in a cat with suspected cardiomyopathy does not exclude disease and should not delay echocardiography if clinical signs warrant it.

Biomarkers in Acute and Critical Care

The critical care setting introduces additional complexity. Patients with systemic inflammatory response syndrome, sepsis, pancreatitis, or trauma may have elevated troponin concentrations from noncardiac causes. The mechanism is multifactorial: cytokine-mediated myocardial depression, microvascular ischemia, and increased wall stress from tachycardia and hypotension. In these patients, troponin elevation indicates myocardial injury but does not by itself establish a diagnosis of primary cardiac disease.

NT-proBNP in critical illness is similarly confounded. Volume resuscitation, acute kidney injury, and systemic inflammation all increase natriuretic peptide concentrations. The biomarker cannot distinguish cardiogenic pulmonary edema from acute respiratory distress syndrome or volume overload from renal failure. The clinician must therefore interpret biomarker results in the context of the full clinical picture, including blood pressure, lactate, oxygenation, and point-of-care ultrasound findings.

The cardiorenal axis deserves specific attention. Acute heart failure and acute kidney injury frequently coexist, and each condition worsens the other. Natriuretic peptides are cleared by renal filtration, so impaired renal function elevates their concentration independent of cardiac status. Troponin is less affected by renal clearance but may be elevated in uremic patients due to subclinical myocardial injury. In a patient with concurrent cardiac and renal disease, biomarker interpretation requires caution, and the clinician should rely more heavily on physical examination, body weight trends, and ultrasound assessment of volume status than on a single biomarker value. The interplay between cardiac and renal dysfunction in critical illness is well described in the human literature, and the same physiologic principles apply to veterinary patients.

Species-Specific Decision Points

The correct use of biomarkers differs between dogs and cats in several respects. In dogs, NT-proBNP has its greatest utility in differentiating cardiac from respiratory dyspnea and in staging myxomatous mitral valve disease. In cats, the assay is most useful for supporting a diagnosis of cardiomyopathy when echocardiography is unavailable, and for risk stratification in cats with suspected subclinical disease.

Troponin interpretation also differs. Dogs with degenerative valve disease typically have normal or mildly elevated troponin concentrations. Marked elevation in a dog with valve disease should prompt investigation for concurrent myocardial injury, such as myocarditis or infarction. Cats with hypertrophic cardiomyopathy frequently have elevated troponin concentrations, and the degree of elevation correlates with the severity of hypertrophy and the presence of systolic anterior motion of the mitral valve.

Patient status changes the decision framework. A stable outpatient with preclinical heart disease does not require serial biomarker measurement. A hospitalized patient with acute dyspnea benefits from a single point-of-care NT-proBNP measurement to guide initial therapy. A patient with known heart failure and suspected decompensation benefits more from home respiratory rate monitoring than from repeated biomarker testing. Equipment availability also matters. Practices without echocardiography rely more heavily on biomarkers to support a cardiac diagnosis. Practices with ultrasound capability use biomarkers as a confirmatory test instead of a primary diagnostic tool.

Documentation of biomarker results should include the assay platform, the result with units, the reference interval for that assay and species, and the clinical interpretation in the context of the patient's presentation. Serial results should be recorded with dates so that trends, instead of single values, inform clinical decisions.

Recognized Complications and Early Detection

Biomarker testing fails in predictable patterns. The most common complication is misinterpretation of a borderline result as diagnostic. A borderline NT-proBNP concentration does not confirm heart disease and does not exclude it. The correct response is to integrate the result with physical examination, thoracic radiography, and echocardiography when available. Serial measurement is more informative than a single borderline value.

False reassurance is a second failure mode. A normal troponin concentration does not exclude myocardial injury, particularly when sampling occurs more than 24 hours after the suspected insult. Troponin I has a relatively short elimination half-life, and transient injury may be missed with delayed sampling. Conversely, a single elevated troponin does not distinguish acute injury from chronic myocardial damage.

Analytical interference produces spurious results. Hemolysis, lipaemia, and sample storage errors affect immunoassay performance. Point-of-care analyzers are more susceptible to these effects than laboratory-based platforms. The discriminating check is to repeat the assay on a fresh sample processed according to the manufacturer's specifications.

Common Errors and Corrective Actions

Less experienced clinicians frequently test the wrong patient. Screening asymptomatic animals with low pretest probability generates false positives that lead to unnecessary echocardiography and owner anxiety. Biomarker testing is most useful when clinical signs or examination findings raise suspicion of cardiac disease.

A second error is treating biomarkers as a substitute for imaging. NT-proBNP and troponin provide complementary information to echocardiography, but they do not measure chamber dimensions, wall thickness, or systolic function. A normal biomarker profile does not exclude structural heart disease, and an elevated profile does not define the lesion.

A third error involves ignoring renal function. Both NT-proBNP and troponin clearance are affected by reduced glomerular filtration. In azotaemic animals, biomarker concentrations must be interpreted with caution, and the magnitude of elevation should be weighed against the degree of renal dysfunction. The same principle applies in critical illness, where concurrent noncardiac disease can elevate biomarkers independently of primary cardiac pathology.

Limitations of Current Evidence

The veterinary biomarker literature is dominated by cross-sectional studies and single-center cohorts. Prospective validation of biomarker-guided treatment decisions remains limited. Expert opinion differs on the utility of serial biomarker monitoring in preclinical disease. Some cardiologists recommend annual NT-proBNP measurement in dogs with Stage B1 myxomatous mitral valve disease, while others argue that no treatment is indicated at this stage and testing therefore adds cost without changing management.

The evidence base for feline biomarkers is similarly constrained. Studies have demonstrated associations between NT-proBNP concentration and the presence of cardiomyopathy, but the optimal cut-off for distinguishing asymptomatic hypertrophic cardiomyopathy from normal cats varies between assays and populations. The ACVIM consensus statements acknowledge these limitations and emphasize that biomarker results should be interpreted within the full clinical context instead of as standalone diagnostic tests.

There is genuine uncertainty regarding the role of troponin in monitoring therapeutic response. Unlike NT-proBNP, which reflects wall stress and neurohormonal activation, troponin indicates myocyte injury. Whether serial troponin measurements guide dose adjustment of pimobendan, ACE inhibitors, or diuretics has not been established. Current practice relies primarily on clinical assessment, body weight, and thoracic radiography for treatment monitoring.

Referral and Escalation Criteria

Referral to a veterinary cardiologist is warranted when biomarker results conflict with clinical findings, when echocardiography is unavailable but the pretest probability of structural heart disease is high, or when serial monitoring is needed to guide therapy in a patient with confirmed disease. Specialist consultation is also appropriate for cats with suspected cardiomyopathy and concurrent thromboembolic risk, where biomarker interpretation carries prognostic weight.

Laboratory involvement is indicated when results seem implausible or when point-of-care and laboratory values disagree. The laboratory can repeat assays, assess sample quality, and clarify reference intervals for the specific analyzer in use. Regulatory reporting is not typically triggered by cardiac biomarker results in companion animals. However, if a biomarker assay is being used in a drug safety study or a clinical trial, the responsible institutional animal care and use committee and any applicable regulatory body should be informed of unexpected elevations, as these may represent drug-induced myocardial toxicity. The translational medicine literature has highlighted the need for consensus on troponin interpretation in preclinical safety evaluation, and veterinary clinicians engaged in such work should follow current guidance from the relevant oversight bodies.

When referral is not feasible, the clinician should document the limitations of the diagnostic workup, communicate prognostic uncertainty to the owner, and schedule re-evaluation at an interval appropriate to the suspected disease. Serial physical examination, body weight, and resting respiratory rate remain the most accessible monitoring tools when advanced diagnostics are unavailable.

Frequently Asked Questions

How Should I Interpret Cardiac Biomarkers When Renal Function Is Impaired?

Renal dysfunction complicates interpretation of both NT-proBNP and troponin. NT-proBNP undergoes renal clearance, so azotemia can elevate concentrations independent of cardiac disease. Troponin is cleared more slowly and may accumulate with severe renal impairment, though the magnitude of effect is smaller than for natriuretic peptides. In azotemic patients, interpret borderline elevations cautiously and rely on trend instead of a single value. A rising NT-proBNP out of proportion to stable renal parameters supports cardiac decompensation. When both cardiac and renal disease are present, biomarkers retain prognostic value but lose diagnostic specificity. The interplay between cardiac and renal dysfunction is well recognized in critical care, where natriuretic peptides and high-sensitivity troponins provide prognostic stratification but require careful interpretation given impaired renal clearance, as described in the cardiorenal syndrome critical care review.

What Do I Do When Point-of-Care Biomarker Testing Is Unavailable?

When in-house assays are unavailable, the diagnostic approach shifts to clinical examination, thoracic imaging, and blood gas analysis. The resting respiratory rate and effort, auscultation findings, and radiographic assessment of pulmonary vasculature and cardiac silhouette often distinguish cardiac from noncardiac respiratory disease. If a laboratory send-out is feasible, request NT-proBNP or troponin with a same-day courier service where turnaround permits. For unstable patients, do not delay emergency treatment pending biomarker results. Biomarker testing supports but does not replace clinical judgment, and proper patient selection and incorporation into existing diagnostic methods determine its value, as outlined in guidance on using cardiac biomarkers in veterinary practice. Document the limitation in the medical record and revisit biomarker testing once the patient stabilizes.

How Do Biomarker Interpretation Strategies Differ Between Dogs and Cats?

Cats present unique interpretive challenges. Their smaller body size and frequent subclinical myocardial disease mean that mild NT-proBNP elevations carry different weight than in dogs. In cats with respiratory signs, a normal NT-proBNP strongly argues against congestive heart failure, whereas an elevated value supports cardiac disease but does not confirm congestion. Cats with hypertrophic cardiomyopathy often show biomarker elevations only after significant atrial enlargement or diastolic dysfunction develops. In dogs, NT-proBNP is more useful for staging myxomatous mitral valve disease and predicting onset of congestive heart failure. Troponin interpretation is similar across species, but reference intervals differ between assays and laboratories. Species-specific decision points are emphasized in veterinary biomarker guidance, and the ACVIM consensus statements provide condition-specific recommendations.

Should I Repeat Biomarker Testing During Routine Recheck Examinations?

Serial monitoring is most valuable in specific scenarios: tracking response to heart failure therapy, detecting progression from preclinical to clinical disease, and assessing risk in patients with equivocal echocardiographic findings. In stable preclinical disease, repeat testing every 6 to 12 months is reasonable. In compensated heart failure, test at each recheck only if the result would alter therapy. A rising NT-proBNP despite stable clinical signs may prompt earlier diuretic adjustment or closer monitoring. Troponin is less useful for serial monitoring of chronic disease because concentrations fluctuate with acute myocardial injury instead of chronic loading conditions. Avoid testing more frequently than clinical decision points require, as cost and owner compliance limit the utility of repeated sampling. The MSD Veterinary Manual provides species-specific guidance on monitoring intervals for common cardiac conditions.

How Do I Explain Biomarker Results to an Owner Who Declines Further Testing?

Frame biomarker results as one piece of a diagnostic picture, not a definitive diagnosis. Explain that the test measures stress on the heart muscle and helps distinguish heart disease from other causes of respiratory signs. If the owner declines echocardiography, state what the biomarker result does and does not establish. A normal result reduces the likelihood of significant heart disease and may justify symptomatic treatment without further cardiac workup. An elevated result supports heart disease but does not quantify severity or guide specific therapy. Offer a practical plan: monitor resting respiratory rate at home, schedule recheck examinations, and revisit advanced imaging if clinical signs progress. Document the discussion and the owner's decision in the medical record. Professional practice resources from the AVMA offer communication frameworks for these conversations.

What Should I Record in the Medical Record Regarding Biomarker Testing?

Record the assay type, laboratory or point-of-care platform, sample quality, and the numerical result with the laboratory's reference interval. Note the timing of sampling relative to clinical signs, fluid therapy, and administration of diuretics or other cardiac drugs. Document the pretest probability that guided test selection and the clinical question the test was intended to answer. If the result is borderline or discordant with clinical findings, record your interpretation and the planned next step. For serial monitoring, record the trend and any changes in therapy prompted by the result. This level of documentation supports continuity of care and defensible medical records. Standardized record keeping aligns with broader quality improvement frameworks described in consensus approaches to clinical assessment, which emphasize structured documentation of investigations and follow-up planning.

Related Clinical & Scientific Guides

• Feline Hepatic Lipidosis: Nutritional and Medical Management
• Canine Respiratory Infection: Diagnostic Approach and Treatment
• Canine Respiratory Virus: Diagnostic and Management Considerations

References and Further Reading

• Current challenges in the evaluation of cardiac safety during drug development: translational medicine meets the Critical Path Initiative.. 2009.
• Standardization of Clinical Assessment, Management and Follow-Up of Acute Hospitalized Exacerbation of COPD: A Europe-Wide Consensus.. 2021.
• Acute cardio-renal and Reno-Cardiac syndromes in critical care.. 2026.
• Models of cardiovascular surgery biobanking to facilitate translational research and precision medicine.. 2022.
• Using Cardiac Biomarkers in Veterinary Practice.. 2015.
• Using cardiac biomarkers in veterinary practice.. 2013.
• ACVIM Consensus Statements. Journal of Veterinary Internal Medicine.
• MSD Veterinary Manual, Professional Edition. MSD Veterinary Manual.
• American Veterinary Medical Association Practice Resources. American Veterinary Medical Association.

Related Articles

• Urinalysis Interpretation in Small Animal Nephrology
• Canine Respiratory Rate Assessment: Techniques and Interpretation
• Canine and Feline Acid-Base Disorders: Interpretation and Management
• Canine Endocrine Testing: Interpretation and Diagnostic Strategy
• Canine Vomiting: Diagnostic Approach for Pancreatitis

This article is educational professional reference material for veterinary audiences. It is not a substitute for veterinary diagnosis, individual clinical judgment, current product labeling, or applicable regulatory requirements.